t
GSK plc announced that Non-Executive Director Dr Hal Barron, SVP James Ford, and President US Maya Martinez-Davis each acquired notional American Depositary Shares (ADS). These acquisitions, resulting from dividend reinvestment within their GSK Executive Supplemental Savings Plan accounts, occurred on May 15, 2026, on the New York Stock Exchange. Dr. Barron acquired 2,300.572 ADSs, Mr. Ford acquired 54.387 ADSs, and Ms. Martinez-Davis acquired 82.387 ADSs, all at a price of $49.6700 per ADS.
| Date | 19 May 2026 |
| Time | 15:30:01 |
| Category | Director/PDMR dealings |
| ID | 9630E |
GSK plc (the 'Company')
Transaction notification
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
Dr Hal Barron |
|||
|
b) |
Position/status |
Non-Executive Director |
|||
|
c) |
Initial notification/ amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GSK plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
American Depositary Shares ('ADS')
ISIN: US37733W2044 |
|||
|
b) |
Nature of the transaction |
Acquisition of notional ADS within Dr Barron's GSK Executive Supplemental Savings Plan account following the reinvestment of dividends
|
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
$49.6700 |
2,300.572 |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information
|
N/A (single transaction) |
|||
|
Aggregated volume Price |
|
||||
|
e) |
Date of the transaction |
2026-05-15 |
|||
|
f) |
Place of the transaction
|
New York Stock Exchange (XNYS) |
|||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
James Ford |
|||
|
b) |
Position/status |
SVP and Group General Counsel, Legal and Compliance |
|||
|
c) |
Initial notification/ amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GSK plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
American Depositary Shares ('ADS')
ISIN: US37733W2044 |
|||
|
b) |
Nature of the transaction |
Acquisition of notional ADS within Mr Ford's GSK Executive Supplemental Savings Plan account following the reinvestment of dividends
|
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
$49.6700 |
54.387 |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information |
N/A (single transaction) |
|||
|
Aggregated volume Price |
|
||||
|
e) |
Date of the transaction |
2026-05-15 |
|||
|
f) |
Place of the transaction
|
New York Stock Exchange (XNYS) |
|||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
Maya Martinez-Davis |
|||
|
b) |
Position/status |
President, US |
|||
|
c) |
Initial notification/ amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GSK plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
American Depositary Shares ('ADS')
ISIN: US37733W2044 |
|||
|
b) |
Nature of the transaction |
Acquisition of notional ADS within Ms Martinez-Davis's GSK Executive Supplemental Savings Plan account following the reinvestment of dividends
|
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
$49.6700 |
82.387 |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information
|
N/A (single transaction) |
|||
|
Aggregated volume Price |
|
||||
|
e) |
Date of the transaction |
2026-05-15 |
|||
|
f) |
Place of the transaction
|
New York Stock Exchange (XNYS) |
|||
About GSK
GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.
Registered in England & Wales:
No. 3888792
Registered Office:
79 New Oxford Street
London
WC1A 1DG